

Date 04/04/2025  
Your Ref  
Our Ref 9846

Enquiries to Richard Mutch  
Extension 35687  
Direct Line 0131 465 5687  
[loth.freedomofinformation@nhs.scot](mailto:loth.freedomofinformation@nhs.scot)  
[richard.mutch@nhs.scot](mailto:richard.mutch@nhs.scot)

Dear

## FREEDOM OF INFORMATION – CANCER PRESCRIBING

I write in response to your request for information in relation to non-small cell lung cancer prescribing.

Question:

1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

Answer:

*Used NSCLC Adjuvant and NSCLC Concurrent with XRT diagnoses*

- Atezolizumab (Tecentriq) 5<
- Durvalumab (Imfinzi) 13
- Nivolumab (Opdivo) 0
- Pembrolizumab (Keytruda) 5<
- Chemotherapy 17 (Carboplatin, Cisplatin, Paclitaxel, Vinorelbine)
- Radiotherapy Available data is not granular enough to answer this question
- Chemotherapy AND Radiotherapy 16
- Osimertinib 5<

Question:

2. How many patients were treated in the past 3 months for gastric cancer (any stage) with:

Answer:

- Can only provide Gastric Cancer + OG Junction
- CAPOX (Capecitabine with Oxaliplatin) 0
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) 0
- Lonsurf (Trifluridine - tipiracil) 0
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5 Fluorouracil or Capecitabine) 5<

Headquarters  
Mainpoint  
102 West Port  
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE  
Chief Executive Professor Caroline Hiscox  
*Lothian NHS Board is the common name of Lothian Health Board*

- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 5<
- Any other systemic anti-cancer therapy 11 (FLOT REGIMEN753, TRASTUZ MD 3 WKLY, NIVOLUMAB R1293, PEMBRO 6WKLY)
- Palliative care only Unknown
- Zolbetuximab (Vyloy) 0

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

Question:

3. How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with:
- CAPOX (Capecitabine with Oxaliplatin)
  - FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
  - Lonsurf (Trifluridine - tipiracil)
  - Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - Zolbetuximab (Vyloy)
  - Any other systemic anti-cancer therapy
  - Palliative care only

Answer:

Can only answer for Gastric and OG Junction combined (see Q2).

Question:

4. How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction?

Answer:

Cannot answer due to disclosure risk associated with answers given to Q2. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

Question:

5. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?

**Answer:**

Available data is not granular enough to provide an answer for this specific stage. Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at [www.itspublicknowledge.info/Appeal](http://www.itspublicknowledge.info/Appeal). If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director, Nursing**  
Cc: Chief Executive